AroCell AB (publ) announces today that Ann Hammarstrand has been appointed as Chief Financial Officer to AroCell, effective beginning of 2017. She will be replacing Bengt Norvik, who is leaving the company to pursue other opportunities.
Ann Hammarstrand has an extensive and comprehensive background as CFO in other industries within the Life Science and financial audit sectors. Ann worked as Certified Public Accountant in the firm of PwC. In 2000, Ann joined Radi Medical Systems in Uppsala, acquired by St Jude Medical Systems in 2009, as Chief Financial Officer.
Since leaving St Jude Medical Systems in 2013, Ann has worked at the County Council of Uppsala in governance and management issues as well as operational development.
- I am pleased to welcome Ann Hammarstrand to AroCell as Chief Financial Officer, says Jan Stålemark, AroCell CEO. Her extensive financial background and global experience within the Life Science industry as CFO and Director of Finance will significantly augment not only our management team but also our business operations in the future. I also want to thank Bengt Norvik sincerely for all his contributions to the company during his time with us and wish all the success in his future endeavours.
For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at16:20 CET on 3 November 2016.
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,700 shareholders. For more information, please seewww.arocell.com. Redeye AB is AroCell:s Certified Adviser.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AroCell AB via Globenewswire